

VIA HAND DELIVERY MARCH 9, 2001

RECEIVED  
MAR 13 2001  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: **COLEMAN et al.**

Application Serial No.: 08/972,301

Art Unit: 1646

Filed: November 18, 1997

Examiner: Kemmerer, E.

For: **Endothelial Monocyte Activating  
Polypeptide III**

Attorney Docket No.: PF206D1

#24  
J.F.J  
3/19/01

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT PURSUANT TO 37 CFR 1.97(c)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references DA-DO listed on the attached Form PTO/SB/08. A copy of each reference is enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), although this Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, the Patent and Trademark Office will consider the Supplemental Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

The Patent Office is authorized to charge the required fee of \$180.00, and any other fee deemed necessary, to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: March 9, 2001

  
Mark J. Hyman (Reg. No. 46,789)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (240) 314-1224

Enclosures